Northcape Wealth Management LLC Has $688,000 Holdings in Pfizer Inc. (NYSE:PFE)

Northcape Wealth Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the third quarter, HoldingsChannel.com reports. The fund owned 23,774 shares of the biopharmaceutical company’s stock after purchasing an additional 419 shares during the period. Northcape Wealth Management LLC’s holdings in Pfizer were worth $688,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer in the 2nd quarter valued at $29,000. Quarry LP bought a new position in Pfizer in the 2nd quarter worth $31,000. Financial Connections Group Inc. bought a new position in Pfizer in the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the 1st quarter worth $37,000. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday. They set an “underperform” rating and a $25.00 target price for the company. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Down 4.7 %

Shares of PFE stock opened at $24.80 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $140.54 billion, a P/E ratio of 33.51, a P/E/G ratio of 0.85 and a beta of 0.67. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a 50-day moving average price of $28.64 and a 200 day moving average price of $28.64.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.17) earnings per share. Research analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.77%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.